Metastatic Her2 Positive Breast Cancer clinical trials

Explore recruiting metastatic her2 positive breast cancer clinical trials.

Recruiting metastatic her2 positive breast cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Metastatic Her2 Positive Breast Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Master Protocol: A Phase 1b / 2, Multicenter, Multi Arm Study of Evorpacept in Combination with Anti-cancer Therapies in Advanced / Metastatic Malignancies (ASPEN-09) Substudy Protocol: A Single-arm Phase 2 Multicenter Study of Evorpacept in Combination with Trastuzumab and Chemotherapy in Participants with Metastatic HER2-Positive Breast Cancer (ASPEN-09-03)

Spain, Italy, France

Therapeutic exploratory (Phase II) EU CTIS Study details

HEROES: De-escalation of medical therapies in HER2-positive metastatic breast cancer in long-term persistent response and minimal residual disease undetectable in circulating tumor DNA

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician’s choice chemotherapy compared to trastuzumab in combination with physician’s choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous trastuzumab deruxtecan treatment

Belgium, France, Spain, Italy, Germany, Austria +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Patient-Centered Study of Trastuzumab Deruxtecan (T-DXd) in First-Line HER2-POsitive Metastatic Breast Cancer with Proactive Toxicity ManagementReflecting Real-World Clinical Practice / TOP-REAL Trial

France, Germany, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A study of the safety, tolerability, biological effect, and efficacy of allogenic natural killer cells in combination with trastuzumab and pertuzumab in adult patients with refractory metastatic Her2 positive breast cancer

Spain

Human Pharmacology (Phase I)- Other EU CTIS Study details

Trastuzumab Deruxtecan (T-DXd): Tailoring Treatment and Companion Diagnostics (CDx) by Liquid Biopsy. DIAMOND STUDY

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Metastatic Her2 Positive Breast Cancer trials by city

Metastatic Her2 Positive Breast Cancer in Toronto Metastatic Her2 Positive Breast Cancer in Vancouver Metastatic Her2 Positive Breast Cancer in Montreal Metastatic Her2 Positive Breast Cancer in Calgary Metastatic Her2 Positive Breast Cancer in Edmonton Metastatic Her2 Positive Breast Cancer in Ottawa Metastatic Her2 Positive Breast Cancer in Winnipeg Metastatic Her2 Positive Breast Cancer in Quebec City Metastatic Her2 Positive Breast Cancer in Hamilton Metastatic Her2 Positive Breast Cancer in Kitchener Metastatic Her2 Positive Breast Cancer in London Metastatic Her2 Positive Breast Cancer in Halifax Metastatic Her2 Positive Breast Cancer in New York Metastatic Her2 Positive Breast Cancer in Los Angeles Metastatic Her2 Positive Breast Cancer in Chicago Metastatic Her2 Positive Breast Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease